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Abstract UDP-N-acetylglucosamine-2-epimerase/N-acetyl-
mannosamine kinase (UDP-GlcNAc 2-epimerase) is the key
enzyme in the de novo synthesis pathway of neuraminic acid,
which is widely expressed as a terminal carbohydrate residue on
glycoconjugates. UDP-GlcNAc 2-epimerase is a bifunctional
enzyme and catalyzes the first two steps of neuraminic acid
synthesis in the cytosol, the conversion of UDP-N-acetyl-
glucosamine to ManAc and the phosphorylation to ManAc-6-
phosphate. So far, regulation of this essential enzyme by
posttranslational modification has not been shown. Since UDP-
N-acetylglucosamine is a cytosolic protein containing eight
conserved motifs for protein kinase C (PKC), we investigated
whether its enzymatic activity might be regulated by phosphor-
ylation by PKC. We showed that UDP-GlcNAc 2-epimerase
interacts with several isoforms of PKC in mouse liver and is
phosphorylated in vivo. Furthermore, PKC phosphorylates UDP-
GlcNAc 2-epimerase and this phosphorylation results in an
upregulation of the UDP-GlcNAc 2-epimerase enzyme activity.
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1. Introduction
Sialylation of glycoproteins and glycolipids plays an impor-
tant role during development and regeneration, and in the
pathogenesis of diseases. Terminal sialic acids are involved
in a variety of cellular interactions, such as cell^cell adhesion
or cell migration [1,2]. The most abundant sialic acid is
N-acetylneuraminic acid (Neu5Ac) [3]. Neu5Ac is synthesized
in the cytosol from UDP-N-acetylglucosamine by four consec-
utive steps. The ¢nal activation of Neu5Ac to CMP-Neu5Ac
prior to its addition to glycoconjugates is catalyzed in the
nucleus. The ¢rst two steps in Neu5Ac biosynthesis are cata-
lyzed by one bifunctional enzyme, UDP-GlcNAc 2-epimerase
[4]. Recently, rat, mouse and human UDP-GlcNAc 2-epimer-
ase have been sequenced and characterized [5^7] and the two
enzymatic activities have been mapped to di¡erent regions of
the polypeptide [8]. As a monomer, the polypeptide has no
enzymatic activity, but its dimer displays N-acetylmannos-
amine kinase activity. When the monomers are assembled to
a hexamer, both UDP-N-acetylglucosamine-2-epimerase and
N-acetylmannosamine kinase (UDP-GlcNAc 2-epimerase) ac-
tivity are detected [4]. It has been shown that UDP-GlcNAc
2-epimerase is the key enzyme of Neu5Ac synthesis, since its
activity is feedback-inhibited by CMP-Neu5Ac [9]. The bio-
logical signi¢cance of the enzyme is illustrated by the obser-
vation that in hepatoma, the low expression of sialic acid is
correlated with a dramatically reduced activity of UDP-
GlcNAc 2-epimerase [10]. In sialuria, a Neu5Ac storage dis-
ease, free sialic acid accumulates in the cytoplasm, and gram
quantities of neuraminic acid are secreted in the urine [11,12].
It has been demonstrated that the metabolic defect involves
lack of feedback inhibition of UDP-GlcNAc 2-epimerase by
CMP-Neu5Ac, resulting in constitutive overproduction of free
Neu5Ac [13]. Furthermore, UDP-GlcNAc 2-epimerase was
found to be a major determinant of cell surface sialylation
in human hematopoietic cell lines and a critical regulator of
the function of speci¢c cell surface adhesion molecules [14].
Since the primary structure of UDP-GlcNAc 2-epimerase con-
tains eight potential phosphorylation sites for protein kinase
C (PKC) (for review, see [15]), an involvement of PKC in the
regulation of the UDP-GlcNAc 2-epimerase enzyme activity
has been suggested. The aim of this study was to illustrate a
possible role of PKC in the regulation of the biosynthesis of
neuraminic acids.
2. Materials and methods
2.1. Cell culture and expression of UDP-GlcNAc 2-epimerase
Spodoptera frugiperda cells (Sf9 cells) were cultured and infected
with recombinant baculovirus containing the coding sequence of the
UDP-GlcNAc 2-epimerase as described [8].
In brief, Sf9 cells were maintained as monolayer cultures in plastic
£asks (Greiner, Frickhausen, Germany) or in suspension by using
Erlenmeyer £asks (100 ml) on orbital shakers (100^120 rpm) at
27‡C. Cells were grown in TC-100 medium supplemented with 2 mM
L-glutamine and 10% fetal calf serum (all from Biochrom, Berlin,
Germany) or in serum-free SF9oo II medium (Gibco BRL). Antibi-
otics (100 U/ml penicillin, 40 U/ml streptomycin) were added to both
culture media.
After growing to a density of 2U106cells/ml, Sf9 cells were infected
with recombinant baculovirus containing the coding sequence of the
UDP-GlcNAc 2-epimerase [8]. During infection, cells are grown in
suspension culture in an orbital shaker at 120 rpm and at 27‡C. After
an optimal infection period of 60 h, the cells were harvested.
2.2. Analytical procedures and antibodies
Protein determination was performed in 96-well enzyme-linked im-
munosorbent assay (ELISA) plates using 100 Wl bicinchionic acid
protein reagent (Pierce) and 25 Wl sample. Plates were evaluated in
a 96-well ELISA reader (Spectra) at 570 nm. Rabbit polyclonal anti-
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bodies against puri¢ed UDP-GlcNAc 2-epimerase from rat liver were
obtained and puri¢ed as described elsewhere [6]. Antibodies to PKC
isoforms were obtained from Transduction Laboratories and all sec-
ondary antibodies were from Dianova (Hamburg, Germany).
2.3. Preparation of cytosol from liver or Sf9 cells
Livers from NMRI mice were removed and transferred to two
volumes ice-cold homogenization bu¡er containing 10 mM NaH2PO4,
1 mM EDTA and a protease inhibitor cocktail (Sigma), pH 7.5. The
tissue was homogenized with an Ultraturrax (Braun Melsungen, Ger-
many) for 1 min at 10 000 rpm. The homogenates were centrifuged for
1 h at 100 000Ug and the supernatants representing the cytosols were
collected. Sf9 cells were homogenized in homogenization bu¡er by
passing them 10 times through a syringe ¢tted with a G22U1.25
needle. Homogenates were then centrifuged for 1 h at 100 000Ug
and the supernatants representing the cytosols were collected.
2.4. Immunoprecipitation
Five mg protein A-agarose (Pharmacia) was precoated with 12 Wg
anti-UDP-GlcNAc 2-epimerase antibodies [6] in phosphate-bu¡ered
saline (PBS) for 2 h at room temperature and washed twice with
PBS. Cytosol was precleared with 5 mg protein A-agarose for 1 h,
then incubated for 2 h at 4‡C with precoated protein A-agarose.
Immunoprecipitates were pelleted by centrifugation, washed three
times with PBS and subjected to sodium dodecyl sulfate (SDS) gel
electrophoresis and immunoblotting.
2.5. Immunoblotting
Samples were separated on 7.5% SDS^polyacrylamide gels and
transferred to nitrocellulose ¢lters. Blots were blocked with 10% fat-
free dry milk powder in PBS, incubated with the primary antibodies,
washed with PBS and incubated with the appropriate secondary anti-
bodies (Sigma, Dianova). After washing, proteins were detected by
enhanced chemiluminescence (Amersham Buchler) according to the
manufacturer’s instructions, and visualized by exposing the blots to
Kodak BioMax ¢lms for time periods between 10 and 120 s. The
antigen detection limit was 50 pg. The coe⁄cient of variation in
amounts of detected antigens was 5^10% in di¡erent experiments.
2.6. In vitro phosphorylation assay
Cytosol of UDP-GlcNAc 2-epimerase-overexpressing Sf9 cells was
puri¢ed by FPLC using a Superdex1 200 column as described by
Hinderlich et al. [4]. Twenty-¢ve Wl enriched aliquots of UDP-GlcNAc
2-epimerase were incubated with [32P]ATP (Hartmann, Braunschweig,
Germany), PKC (Biomol, Hamburg, Germany) in the presence and
absence of phorbol 12-myristate 13-acetate (PMA) or staurosporine
(Biomol, Hamburg, Germany) for 10, 20 or 60 min at 37‡C followed
by SDS gel electrophoresis and phosphoimaging (Molecular Dynam-
ics).
2.7. In vivo phosphorylation assay
Sf9 cells were infected with recombinant baculovirus containing the
coding sequence of the UDP-GlcNAc 2-epimerase. Twelve hours after
infection, 1 mCi [32P]H3PO4 (Hartmann, Braunschweig, Germany)
was added to the cultures. Fourty-eight hours after infection, cells
were homogenized and UDP-GlcNAc 2-epimerase was immunopreci-
pitated and subjected to SDS gel electrophoresis and phosphoimaging.
2.8. Quanti¢cation of UDP-GlcNAc 2-epimerase activity
UDP-GlcNAc 2-epimerase activity was measured by a previously
published modi¢ed method [16]. In brief, the ¢nal volume of incuba-
tion mixtures was 225 Wl, incubations were carried out at 37‡C for
30 min, and reactions were stopped by addition of 350 Wl ethanol.
UDP-GlcNAc 2-epimerase assay: 45 mM Na2HPO4, pH 7.5, 10 mM
MgCl2, 1 mM UDP-GlcNAc, 25 nCi of UDP-(14C)-GlcNAc (NEN,
Dreieich, Germany). Five Wl of radiolabeled compounds was sepa-
rated by thin layer chromatography using HPTLC plates (Merck,
Darmstadt, Germany) and the following eluent: (n-propanol:1 M
sodium acetate pH 5:water = 7:1:2, vol.). Radioactivity was deter-
mined using a phosphoimager.
3. Results
3.1. Several PKC isoforms are associated with UDP-GlcNAc
2-epimerase in mouse liver
In a ¢rst series of experiments, we analyzed the isoform
expression of PKC in rat liver. Freshly prepared cytosol
from mouse liver was analyzed by Western blotting and
probed with PKC isoform-speci¢c antibodies. Fig. 1A illus-
trates that in mouse liver, PKC isoforms Q, S, V, W and j are
expressed and that PKC isoforms K, L, N, O and a are not
detectable. Since the primary structure of the murine UDP-
GlcNAc 2-epimerase contains eight consensus sites for PKC
phosphorylation, we analyzed immunoprecipitates of UDP-
GlcNAc 2-epimerase from mouse liver cytosol with PKC iso-
form-speci¢c antibodies. All PKC isoforms expressed in
mouse liver (Q, S, V, W and j) were detected by co-immunopre-
cipitation with UDP-GlcNAc 2-epimerase antibodies (Fig.
1B). For control, the experiments were also performed in
the absence of UDP-GlcNAc 2-epimerase-speci¢c antibodies
where no isoform of PKC could be detected (data not shown).
3.2. In vivo phosphorylation of UDP-GlcNAc 2-epimerase
Since UDP-GlcNAc 2-epimerase contains eight potential
phosphorylation sites for PKC, we addressed the question
Fig. 1. A: Western blot analysis of PKC isoforms in mouse liver. Cytosol of mouse liver was separated on a 7.5% SDS^PAGE gel and ana-
lyzed with isoform-speci¢c PKC antibodies. B: Co-immunoprecipitation of PKC isoforms with UDP-GlcNAc 2-epimerase. UDP-GlcNAc 2-epi-
merase was immunoprecipitated from cytosol of mouse liver. Precipitates were separated on a 7.5% SDS^PAGE gel and analyzed for co-immu-
noprecipitated proteins with isoform-speci¢c PKC antibodies.
Fig. 2. In vivo phosphorylation of UDP-GlcNAc 2-epimerase.
UDP-GlcNAc 2-epimerase-overexpressing cells were allowed to
grow in medium containing radiolabeled phosphate. After 48 h, cells
were lysed and UDP-GlcNAc 2-epimerase was immunoprecipitated
and subjected to Western blotting (WB) and autoradiography (AU).
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whether UDP-GlcNAc 2-epimerase is phosphorylated in vivo.
Therefore, we incubated Sf9 cells with radiolabeled H3PO4
12 h after infection with recombinant baculovirus containing
the coding sequence of the UDP-GlcNAc 2-epimerase.
Fourty-eight hours after infection, cells were homogenized
and UDP-GlcNAc 2-epimerase was immunoprecipitated
from the cytosol and subjected to SDS gel electrophoresis,
Western blotting and autoradiography. The immunoprecipi-
tated UDP-GlcNAc 2-epimerase was detected with UDP-
GlcNAc 2-epimerase-speci¢c antibodies (Fig. 2, WB), and in-
corporation of phosphate was shown by autoradiography
(Fig. 2, AU), indicating that UDP-GlcNAc 2-epimerase is
phosphorylated in vivo.
3.3. In vitro phosphorylation of UDP-GlcNAc 2-epimerase
UDP-GlcNAc 2-epimerase is not only associated with PKC
isoforms; as shown by in vitro phosphorylation experiments,
it is also a substrate of PKC. Puri¢ed UDP-GlcNAc 2-epi-
merase from the cytosol of overexpressing Sf9 cells was incu-
bated with radiolabeled ATP in the absence and presence of
PKC. Additionally, these experiments were performed in the
absence and presence of PMA, an activator of PKC, and
staurosporine, an inhibitor of serine/threonine kinases. After
incubation times between 10 and 60 min, UDP-GlcNAc
2-epimerase was analyzed by autoradiography after SDS^
polyacrylamide gel electrophoresis (PAGE). PKC phosphory-
lated UDP-GlcNAc 2-epimerase within 10 min, and an in-
creased incubation time led to an increased phosphorylation
of UDP-GlcNAc 2-epimerase (Fig. 3C). Addition of the PKC
stimulating agent, PMA, did not lead to increased phosphor-
ylation (Fig. 3D), whereas addition of staurosporine com-
pletely abolished phosphorylation of UDP-GlcNAc 2-epimer-
ase (Fig. 3B). For control, the experiment was also performed
in the absence of PKC (Fig. 3A). In all experiments, gels were
stained with Coomassie blue to con¢rm equal loading of all
lanes.
3.4. Modulation of UDP-GlcNAc 2-epimerase enzyme activity
by phosphorylation
We not only demonstrated that UDP-GlcNAc 2-epimerase
is phosphorylated by PKC, but also that its enzyme activity is
upregulated after PKC-dependent phosphorylation. In vitro,
UDP-GlcNAc 2-epimerase enzyme activity was determined
after incubation of the enzyme with PKC in the absence
and presence of PMA and staurosporine. Incubation of the
UDP-GlcNAc 2-epimerase with PKC alone resulted in an
increase of the enzyme activity by 30%. In the presence of
the PKC and the PKC activator PMA, this enzyme activity
increased again between 25% and 48%, resulting in a total
increase between 50% and 100% compared to the control
conditions in the absence of PKC. In the presence of the
serine/threonine kinase inhibitor, staurosporine, the enzyme
activity of the UDP-GlcNAc 2-epimerase remained un-
Fig. 3. In vitro phosphorylation of UDP-GlcNAc 2-epimerase. Autoradiogram: puri¢ed UDP-GlcNAc 2-epimerase was incubated in the pres-
ence of [32P]ATP with PMA, staurosporine or PKC according to the underlying scheme. After incubation times of 10, 20 or 60 min, the mix-
ture of molecules was subjected to electrophoresis and phosphorylated UDP-GlcNAc 2-epimerase was visualized by autoradiography. Coomas-
sie blue staining: for control, the gel was stained with Coomassie blue to con¢rm equal loading of all lanes. All lanes contain a similar amount
of UDP-GlcNAc 2-epimerase protein indicated by equal staining of the 70 kDa band.
Fig. 4. Modulation of the enzymatic activity of the UDP-GlcNAc
2-epimerase. A: UDP-GlcNAc 2-epimerase was incubated with (+)
and without PKC (3) in the absence (control) or presence of PMA
(PMA) or staurosporine (staurosporine). One representative autora-
diogram of an HPTLC plate showing the reaction product (ManAc)
is shown. B: Enzymatic activity of UDP-GlcNAc 2-epimerase was
determined by quanti¢cation of the reaction product on HPTLC
plates and computer analysis. One representative out of four inde-
pendent experiments is shown.
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changed compared to the situation in the presence of PKC.
Fig. 4 illustrates the results of one representative experiment.
Fig. 4A shows the autoradiogram of an HPTLC plate of the
reaction product, ManAc, after the epimerization of UDP-
GlcNAc in the absence and presence of PMA and staurospo-
rine. In this particular experiment, the presence of PKC and
PMA results in an increase of UDP-GlcNAc 2-epimerase en-
zyme activity by 100% (Fig. 4B).
4. Discussion
Neu5Ac is the most common naturally occurring sialic acid
and terminal carbohydrate of a variety of glycoconjugates [2].
UDP-GlcNAc 2-epimerase has been shown to be the key en-
zyme of Neu5Ac biosynthesis in rat liver, and it is a regulator
of cell surface sialylation [4,14]. In this study, we demon-
strated that UDP-GlcNAc 2-epimerase is associated with
PKC isoforms in liver and is phosphorylated in vivo. Further-
more, UDP-GlcNAc 2-epimerase is a substrate for PKC in
vitro and we provide evidence that its basal enzyme activity is
upregulated after phosphorylation by PKC. To our knowl-
edge, this is the ¢rst report on a direct involvement of PKC
in the biosynthesis of carbohydrate structures. PKC activity is
known to be upregulated during hyperglycemia [17] but there
is no published evidence that PKC is directly involved in
glycan biosynthesis.
UDP-GlcNAc 2-epimerase is a bifunctional enzyme and it
catalyzes not only the epimerization of UDP-GlcNAc to
ManAc but also the phosphorylation of ManAc to ManAc-
phosphate [4]. The enzyme activity of the UDP-GlcNAc 2-
epimerase is regulated by feedback inhibition by CMP-Neu5-
Ac. CMP-Neu5Ac is the activated endproduct of neuraminic
biosynthesis and is a substrate of several sialyltransferases in
the Golgi apparatus. Furthermore, the oligomeric state is a
possible regulator of the enzyme activity. In vitro, the oligo-
merization of UDP-GlcNAc 2-epimerase is dependent on
UDP-GlcNAc, since UDP-GlcNAc stabilizes the hexameric
state [4]. The UDP-GlcNAc 2-epimerase is only active when
assembled as a hexamer. Until now, no additional regulatory
mechanism has been described. Since phosphorylation of
ManAc to ManAc-phosphate can also be catalyzed by
GlcNAc kinase [18] and epimerization is the initial step in
neuraminic acid synthesis, we concentrated our study on the
regulation of the UDP-GlcNAc 2-epimerase activity. The pri-
mary sequence of rat, mouse and human UDP-GlcNAc
2-epimerase contains eight potential PKC consensus sites.
Therefore, we focused our experiments on UDP-GlcNAc
2-epimerase interactions with PKC in liver, since this is the
organ with the highest UDP-GlcNAc 2-epimerase expression.
We propose that PKC, a key element in various signal trans-
duction pathways, phosphorylates and regulates the enzy-
matic activity of the UDP-GlcNAc 2-epimerase and might
therefore be involved in cell surface sialylation. The exact
mechanism of PKC-mediated phosphorylation of UDP-
GlcNAc 2-epimerase in vivo will be the subject of future in-
vestigations.
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